An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Acorda Therapeutics
With
Prometrika, LLC
BCS Consulting, Inc.
Longitudinal study design
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of multiple sclerosis
Receiving Ampyra® consistently for at least 2 weeks prior to the screening visit
No history of seizures except simple febrile seizures
You may not be if
Sexually active woman of childbearing potential who is not surgically sterile, \<two years post-menopause or is not using effective birth control methods
Subject who is pregnant or breastfeeding
Clareo Health | An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)
